07.21.14
Headquarters: Dublin, Ireland
twitter.com/Actavis
www.actavis.com
Top Selling Drugs
(The company’s portfolio of approximately 45 brand pharmaceutical products represented approximately 80% of total Actavis Specialty Brands segment product revenues in 2013)
The last few years have been quite a ride for the company formerly known as Watson Pharmaceuticals. Each year has brought another mega merger and change.
The Corona, California generics and specialty company acquired the Swiss Actavis Group in 2012, a move that brought it more specialty pharmaceuticals and also more name recognition in key markets such as Russia. It later added Warner Chilcott PLC in 2013 for $9.2 billion and this year, bought Forest Labs for $25 billion.
Tax Savings Offshore
The company moved its headquarters from Corona to Parsippany, NJ and has since moved them to Dublin, Ireland, where Warner Chilcott was based, a move that offers heavy tax benefits. However, Chairman Paul Bisaro is still based in Parsippany, media report.
Actavis already had a collaboration agreement with Amgen to develop oncology biosimilars, and now has five biosimilars in development in oncology, women’s health and other areas.
Last year, the company launched new generic pharmaceuticals globally, including generic versions of Diovan, Lidoderm and Cymbalta. Actavis has API production capacity in Coleraine, Northern Ireland, and Ambernath, India.
The company’s third party agency Medis, outlicenses generics, offering a portfolio of 175 products for outlicensing to 330 customers, mainly in Europe.
Focus on hard to manufacture drugs that are off patent
Actavis’ focus is primarily on off patent drugs that are difficult to make, or that complement its existing products, the company wrote in its Annual Report. Actavis owns more than 35 manufacturing facilities around the world.
In other cases, the company applies novel delivery methods, such as sustained release or transdermal patches, to proprietary drug forms. As of last December, Actavis had filed over 195 ANDAs in the U.S. alone.
Actavis has implemented cost reduction initiatives, including the implementation of operational excellence at its manufacturing facilities. The company plans to close its Pharmapack facility in the Netherlands this year and its Lincolnton NC facility by 2015, moving existing sections to Salt Lake City.
Teva settles on Generic Celebex
The company has been sued by Vivus, which had submitted an ANDA for generic Qsymia. Teva has settled with it on the issue of generic Celebrex, which is due to be launched by December.
Last month, the company appointed Brenton Saunders, former CEO at Forest Labs, CEO of Actavis. According to an article last month in Fortune magazine, Saunders has the reputation of a turnaround specialist, and he had reportedly gotten Forest Labs out of a slump.
Fortune also reported that top executives at the company received up to $185 million in “merger success awards.” CEO Saunders, for instance, would get $15 million to start and up to $68.5 once predefined goals are met.
twitter.com/Actavis
www.actavis.com
Headcount: | 17,000 | |
Year Established: | 2013 | |
Pharma Revenues: | $8,677 | 47% |
Net Income: | $750 | 600% |
R&D Budget: | $617 | 53% |
Top Selling Drugs
Drug | Indication |
Actonel Risedronate | osteoporosis |
Androderm patch | male testosterone replacement |
Asacol HD | ulcerative colitis |
Telvia Risedronate | osteoporosis |
Crinone | progesterone supplementation |
Delzicol Mesalamine | ulcerative colitis |
Doryx Doxycycline | hyclate acne |
Enablex Darifenacin | overactive bladder |
Estrace Cream Estradiol | hormone therapy |
Generess | oral contraceptive |
INFeD Iron | hematinic |
Kadian | opioid analgesic |
Lo Loestrin | oral contraceptive |
Minastrin 24 F | oral contraceptive |
Oxytrol Oxybutnin | overactive bladder |
Rapaflo Silodosin | benign prostatic hyperplasia |
Trelstar Triptorelin | prostate cancer |
The last few years have been quite a ride for the company formerly known as Watson Pharmaceuticals. Each year has brought another mega merger and change.
The Corona, California generics and specialty company acquired the Swiss Actavis Group in 2012, a move that brought it more specialty pharmaceuticals and also more name recognition in key markets such as Russia. It later added Warner Chilcott PLC in 2013 for $9.2 billion and this year, bought Forest Labs for $25 billion.
Tax Savings Offshore
The company moved its headquarters from Corona to Parsippany, NJ and has since moved them to Dublin, Ireland, where Warner Chilcott was based, a move that offers heavy tax benefits. However, Chairman Paul Bisaro is still based in Parsippany, media report.
Actavis already had a collaboration agreement with Amgen to develop oncology biosimilars, and now has five biosimilars in development in oncology, women’s health and other areas.
Last year, the company launched new generic pharmaceuticals globally, including generic versions of Diovan, Lidoderm and Cymbalta. Actavis has API production capacity in Coleraine, Northern Ireland, and Ambernath, India.
The company’s third party agency Medis, outlicenses generics, offering a portfolio of 175 products for outlicensing to 330 customers, mainly in Europe.
Focus on hard to manufacture drugs that are off patent
Actavis’ focus is primarily on off patent drugs that are difficult to make, or that complement its existing products, the company wrote in its Annual Report. Actavis owns more than 35 manufacturing facilities around the world.
In other cases, the company applies novel delivery methods, such as sustained release or transdermal patches, to proprietary drug forms. As of last December, Actavis had filed over 195 ANDAs in the U.S. alone.
Actavis has implemented cost reduction initiatives, including the implementation of operational excellence at its manufacturing facilities. The company plans to close its Pharmapack facility in the Netherlands this year and its Lincolnton NC facility by 2015, moving existing sections to Salt Lake City.
Teva settles on Generic Celebex
The company has been sued by Vivus, which had submitted an ANDA for generic Qsymia. Teva has settled with it on the issue of generic Celebrex, which is due to be launched by December.
Last month, the company appointed Brenton Saunders, former CEO at Forest Labs, CEO of Actavis. According to an article last month in Fortune magazine, Saunders has the reputation of a turnaround specialist, and he had reportedly gotten Forest Labs out of a slump.
Fortune also reported that top executives at the company received up to $185 million in “merger success awards.” CEO Saunders, for instance, would get $15 million to start and up to $68.5 once predefined goals are met.